skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Neurological and neuropsychiatric aspects of tuberous sclerosis complex
Material Type:
Article
Add to My Research

Neurological and neuropsychiatric aspects of tuberous sclerosis complex

Lancet neurology, 2015-07, Vol.14 (7), p.733-745 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2015 ;ISSN: 1474-4422 ;EISSN: 1474-4465 ;DOI: 10.1016/S1474-4422(15)00069-1 ;PMID: 26067126 ;CODEN: LANCAO

Full text available

2
Tuberous sclerosis
Material Type:
Article
Add to My Research

Tuberous sclerosis

The Lancet (British edition), 2008-08, Vol.372 (9639), p.657-668 [Peer Reviewed Journal]

Elsevier Ltd ;2008 Elsevier Ltd ;2008 INIST-CNRS ;Copyright Elsevier Limited Aug 23-Aug 29, 2008 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(08)61279-9 ;PMID: 18722871 ;CODEN: LANCAO

Full text available

3
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
Material Type:
Article
Add to My Research

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2153-2163 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 29, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)31419-2 ;PMID: 27613521 ;CODEN: LANCAO

Full text available

4
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Material Type:
Article
Add to My Research

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2013-01, Vol.381 (9861), p.125-132 [Peer Reviewed Journal]

Elsevier Ltd ;2013 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 12, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61134-9 ;PMID: 23158522 ;CODEN: LANCAO

Full text available

5
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
Material Type:
Article
Add to My Research

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

The lancet oncology, 2014-12, Vol.15 (13), p.1513-1520 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 2014 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(14)70489-9 ;PMID: 25456370 ;CODEN: LANCAO

Full text available

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2008  (1)
  2. 2008 To 2012  (1)
  3. 2013 To 2013  (1)
  4. 2014 To 2015  (2)
  5. After 2015  (1)
  6. More options open sub menu

Searching Remote Databases, Please Wait